vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and enCore Energy Corp. (EU). Click either name above to swap in a different company.
enCore Energy Corp. is the larger business by last-quarter revenue ($12.4M vs $10.7M, roughly 1.2× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -173.9%, a 197.4% gap on every dollar of revenue.
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Devon Energy Corporation is an American company engaged in hydrocarbon exploration. It is organized in Delaware with operational headquarters in the 50-story Devon Energy Center in Oklahoma City, Oklahoma. Its operations are in the Delaware Basin, Eagle Ford Group, and the Rocky Mountains.
ABUS vs EU — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $12.4M |
| Net Profit | $2.5M | $-21.5M |
| Gross Margin | — | 37.9% |
| Operating Margin | 13.9% | -135.9% |
| Net Margin | 23.5% | -173.9% |
| Revenue YoY | 522.2% | — |
| Net Profit YoY | 112.7% | — |
| EPS (diluted) | $0.01 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.4M | ||
| Q3 25 | — | $8.9M | ||
| Q2 25 | $10.7M | $3.7M | ||
| Q1 25 | — | $18.2M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | — | ||
| Q2 23 | $4.7M | — | ||
| Q1 23 | $6.7M | — |
| Q4 25 | — | $-21.5M | ||
| Q3 25 | — | $-4.8M | ||
| Q2 25 | $2.5M | $-6.3M | ||
| Q1 25 | — | $-24.2M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | — | ||
| Q2 23 | $-17.1M | — | ||
| Q1 23 | $-16.3M | — |
| Q4 25 | — | 37.9% | ||
| Q3 25 | — | 43.8% | ||
| Q2 25 | — | 30.8% | ||
| Q1 25 | — | -0.1% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | — | -135.9% | ||
| Q3 25 | — | -158.2% | ||
| Q2 25 | 13.9% | -526.1% | ||
| Q1 25 | — | -85.7% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — | ||
| Q2 23 | -395.3% | — | ||
| Q1 23 | -260.4% | — |
| Q4 25 | — | -173.9% | ||
| Q3 25 | — | -53.7% | ||
| Q2 25 | 23.5% | -172.7% | ||
| Q1 25 | — | -132.9% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — | ||
| Q2 23 | -367.5% | — | ||
| Q1 23 | -244.3% | — |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | $0.01 | $-0.03 | ||
| Q1 25 | — | $-0.13 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — | ||
| Q2 23 | $-0.10 | — | ||
| Q1 23 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $52.4M |
| Total DebtLower is stronger | $0 | $110.0M |
| Stockholders' EquityBook value | $83.0M | $229.2M |
| Total Assets | $103.3M | $430.4M |
| Debt / EquityLower = less leverage | 0.00× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $91.9M | ||
| Q2 25 | $37.4M | $26.9M | ||
| Q1 25 | — | $29.7M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | — | ||
| Q2 23 | $27.2M | — | ||
| Q1 23 | $40.6M | — |
| Q4 25 | — | $110.0M | ||
| Q3 25 | — | $109.3M | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — | ||
| Q1 23 | $0 | — |
| Q4 25 | — | $229.2M | ||
| Q3 25 | — | $248.6M | ||
| Q2 25 | $83.0M | $264.7M | ||
| Q1 25 | — | $267.9M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | — | ||
| Q2 23 | $134.7M | — | ||
| Q1 23 | $143.9M | — |
| Q4 25 | — | $430.4M | ||
| Q3 25 | — | $441.9M | ||
| Q2 25 | $103.3M | $359.4M | ||
| Q1 25 | — | $362.6M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | — | ||
| Q2 23 | $176.8M | — | ||
| Q1 23 | $191.2M | — |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.44× | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — | ||
| Q1 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $12.9M |
| Free Cash FlowOCF − Capex | — | $7.2M |
| FCF MarginFCF / Revenue | — | 57.8% |
| Capex IntensityCapex / Revenue | 0.0% | 46.7% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-45.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $12.9M | ||
| Q3 25 | — | $-20.3M | ||
| Q2 25 | $-15.7M | $-9.9M | ||
| Q1 25 | — | $-7.7M | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-19.6M | — | ||
| Q1 23 | $-27.3M | — |
| Q4 25 | — | $7.2M | ||
| Q3 25 | — | $-26.3M | ||
| Q2 25 | — | $-14.1M | ||
| Q1 25 | — | $-11.7M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — | ||
| Q1 23 | $-27.4M | — |
| Q4 25 | — | 57.8% | ||
| Q3 25 | — | -296.6% | ||
| Q2 25 | — | -385.2% | ||
| Q1 25 | — | -64.1% | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — | ||
| Q1 23 | -410.0% | — |
| Q4 25 | — | 46.7% | ||
| Q3 25 | — | 68.0% | ||
| Q2 25 | 0.0% | 115.1% | ||
| Q1 25 | — | 21.7% | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — | ||
| Q1 23 | 1.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
